Most Recent

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (6/4/21) "Momentum continues to build for VIV."

Algernon Pharmaceuticals Inc.

Sam Riches, Weekend Dispensary (5/22/21) "AGN received positive FDA feedback on its planned Phase 1 trial."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (5/4/21) "We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (4/26/21) "VIV received a purchase order for 4.4 mt of OxC-beta Livestock."

Avivagen Inc.

David Bautz, Zacks Small-Cap Research (3/8/21) "VIV's orders received thus far for 2021 exceed last year's totals."

Biotechnology / Pharmaceuticals

Algernon Pharmaceuticals Inc.

Sam Riches, Weekend Dispensary (5/22/21) "AGN received positive FDA feedback on its planned Phase 1 trial."

Algernon Pharmaceuticals Inc.

André Uddin, Research Capital Corporation (3/1/21) "Final results from AGN's Phase 2b COVID-19 trial are expected soon."

Algernon Pharmaceuticals Inc.

André Uddin, Research Capital Corporation (2/2/21) "AGN is to continue a number of preclinical studies of DMT for stroke."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (2/1/21) "AGN is starting clinical research with a psychedelic drug for stroke."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (12/28/20) "The least we can expect with AGN is a significant bounce from here."

Healthcare Services

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (1/8/21) "The slight drop today [of RHT shares] on very low volume is interpreted as a sign that it is ready to turn higher again now or very soon, and it is therefore rated an immediate buy."

Reliq Health Technologies Inc.

Nick Hodge, Outsider Club (3/28/16) "MSD is pursuing a roll-up strategy whereby it will grow through acquisitions that could lead it to several million in revenue in fairly short order."

Reliq Health Technologies Inc.

GeoInvesting (12/29/15) "MSD continues to maximize the value of its assets through potential partnerships and/or acquisitions."

Life Sciences Tools & Diagnostics

Reliq Health Technologies Inc.

Chris Parry, Equity Guru (10/5/17) "RHT now has 1000 patients into their system from two customers, and expect somewhere between 2000 and 2500 to be added next month."

Medical Devices

Reliq Health Technologies Inc.

Chris Parry, Equity Guru (10/5/17) "RHT now has 1000 patients into their system from two customers, and expect somewhere between 2000 and 2500 to be added next month."

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (9/22/17) "RHT is a pioneer in technologies that allow hospital patients to return home sooner."

Reliq Health Technologies Inc.

Michael Berger, TalkMarkets (9/6/17) "August was a banner month for RHT and these developments have the firm positioned for incremental growth."

Reliq Health Technologies Inc.

Nick Hodge, Outsider Club (3/28/16) "MSD is pursuing a roll-up strategy whereby it will grow through acquisitions that could lead it to several million in revenue in fairly short order."

Reliq Health Technologies Inc.

GeoInvesting (12/29/15) "MSD continues to maximize the value of its assets through potential partnerships and/or acquisitions."

Nutraceuticals

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (5/4/21) "We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

Avivagen Inc.

SmallCapsDaily (7/23/20) "VIV is building a compelling growth story as it has gone on to receive numerous country approvals across many large livestock markets in the world."

Avivagen Inc.

Clive Maund, CliveMaund.com (5/11/19) "This looks like an excellent point to buy back VIV."